# E2E Pharmacovigilance Planning - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/e2e-pharmacovigilance-planning/89ea2b55-7e7d-4a99-9e7f-9aac73abf09b

> FDA guidance document: E2E Pharmacovigilance Planning. Issue date: April 01, 2005. Get complete insights and analysis.

---

## Details

- Title: E2E Pharmacovigilance Planning
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2005-04-01
- Last Changed: 2020-04-20
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2004-D-0245">FDA-2004-D-0245</a>

## Related Documents

- [Premarketing Risk Assessment:  Guidance for Industry](https://www.globalkeysolutions.net/guidances/guidance-document/premarketing-risk-assessment-guidance-for-industry/232a7962-0cba-49be-a6b4-356c35b5f91f)
- [Q1E Evaluation of Stability Data](https://www.globalkeysolutions.net/guidances/guidance-document/q1e-evaluation-of-stability-data/e4413f7a-4a88-4baf-b13c-f5314f2b7f64)
- [Q1A(R2) Stability Testing of New Drug Substances and Products](https://www.globalkeysolutions.net/guidances/guidance-document/q1ar2-stability-testing-of-new-drug-substances-and-products/91828b9f-0f69-4b32-8309-b0a7cc4ba7f1)